Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of custirsen plus docetaxel/prednisone versus docetaxel/prednisone in metastatic castration-resistant prostate cancer
2010-021011-16Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2010
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of custirsen in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Overall survival. Started Aug 2010; status: completed.
02
Drugs
custirsen
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2010-021011-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021011-16.